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Aim. Fenretinide, a synthetic retinoid derivative first investigated for cancer 
prevention and treatment, has been shown to ameliorate glucose tolerance and the 
plasma lipid profile, and to reduce body fat mass. These effects, together with its 
ability to inhibit ceramide synthesis, have suggested that fenretinide may display anti-
atherosclerotic effects. 
Methods. To this aim, 9-weeks-old apoE-knockout (EKO) female mice were fed for 
12 weeks a Western diet, without (EKO-Ctrl) or with (0.1% w/w) fenretinide (EKO-
Fen). As a reference, wild-type (WT) mice were likewise treated. Growth and 
metabolic parameters were monitored throughout the study. Atherosclerosis 
development was evaluated in the aorta and at the aortic sinus. Blood and lymphoid 
organs were further characterized with thorough cytological/histological and 
immunocytofluorimetric analyses. 
Results. Fenretinide treatment significantly lowered body weight, glucose levels and 
plasma levels of total cholesterol, triglycerides and phospholipids. In the liver, 
fenretinide remarkably reduced hepatic glycogenosis and steatosis driven by the 
Western diet. Treated spleens were abnormally enlarged, with severe follicular 
atrophy and massive extramedullary hematopoiesis. Severe renal hemosiderin 
deposition was observed in EKO-Fen. Treatment resulted in a threefold increase of 
total leukocytes (WT and EKO) and raised the activated/resting monocyte ratio in 
EKO-Fen. Finally, atherosclerosis development was markedly increased at the aortic 
arch (34.4Å}7.3% vs 26.1Å}5.8%, +32%), thoracic (14.3Å}4.9% 
vs 4.9Å}2.1%, +191%) and abdominal aorta (7.6Å}3.3% vs 3.3Å}1.8%,+130%) of 
fenretinide-treated mice. Plaque extent was further quantified at the aortic sinus and 
provided similar results (810.000 µm2 vs. 540.000 µm2, +50% in EKO-Fen). Plaques 
of treated mice were characterized by an increased collagen content and a larger 
necrotic core, whereas the area occupied by macrophages, foam cells and neutral 
lipids was comparable between EKO-Fen and EKO-Ctrl. 
Conclusion. We provide the first evidence that, despite beneficial metabolic effects, 
fenretinide treatment may prove detrimental for atherosclerosis development. 
